Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
Events next week:
It's listings galore next week! There will be a debut every day spanning from Australia to Korea and India then back to Hong Kong to close off the week.
In Hong Kong, we took a final look at Clover Biopharmaceuticals (2197 HK), Beijing Airdoc Technology (2251 HK),Uju Holding (1948 HK), and ANE Logistics (1292621D CH) IPOs and shared our thoughts on valuation.
We also initiated on HeMo Bioengineering (HMB HK), a China-based interventional medical device company with a focus on neuro-vascular and peripheral diseases.
India ECM busy as ever. FSN E-Commerce Ventures (Nykaa) (1003622D IN) and Policybazaar Insurance Web Aggregator (1569999D IN) launched their IPO bookbuilds. Nykaa will close its bookbuild on Monday and look to list on 11th November while PolicyBazaar will close its bookbuild on 4th November.
Paytm (PAYTM IN) will launch India’s biggest IPO the week after with anchor books closing on 5th November.
In Australia, unfortunately, the much awaited SG Lottery (SGL AU) did not make it to its IPO. The company was acquired by Brookfield. For debuts, GQG Partners (GQG AU) opened higher on Monday but struggled to stay above IPO price for the rest of the week as expected.
Whereas APM (1934849D AT), an international human services provider company, closed its institutional bookbuild this week and will look to list on 16th November.
Finally, in Indonesia, Mitratel (1319Z IJ) opened books for its IPO, looking to raise about US$1.3bn. We thought that valuation is attractive towards the low-end of the price range. Books will close this Thursday and list on 22nd November.
Placements also kept us busy this week and they were sizable ones with deal size more than US$1bn, with the exception of China Yuhua Education (6169 HK). Overall, placement performance was shaky. Yuhua collapsed lower after breaking its deal price on trade date while Li Ning is also trading below its deal price. But we think that BYD and Macquarie should up well on Monday owing to favorable deal dynamics.
Last, but not least, tearsheet for the week:
Our overall accuracy rate is 73.7% for IPOs and 67.9% for Placements
(Performance measurement criteria is explained at the end of the note)
Hong Kong/China
US/China ADR
India
Japan/Korea
Others
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.